Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
about
Efficacy of muscle exercise in patients with muscular dystrophy: a systematic review showing a missed opportunity to improve outcomes.Gene therapy in large animal models of muscular dystrophy.SLIMMER (FHL1B/KyoT3) interacts with the proapoptotic protein Siva-1 (CD27BP) and delays skeletal myoblast apoptosis.Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis.PhiC31 integrase-mediated genomic integration and stable gene expression in the mouse mammary gland after gene electrotransfer.
P2860
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@en
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@nl
type
label
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@en
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@nl
prefLabel
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@en
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@nl
P2860
P356
P1476
Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
@en
P2093
Anthony Scimè
Michael A Rudnicki
P2860
P2888
P304
P356
10.1007/BF03256275
P577
2008-01-01T00:00:00Z